84 related articles for article (PubMed ID: 31656047)
1. Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view.
Thielen FW; van Dongen-Leunis A; Arons AMM; Ladestein JR; Hoogerbrugge PM; Uyl-de Groot CA
Eur J Haematol; 2020 Aug; 105(2):203-215. PubMed ID: 32289184
[TBL] [Abstract][Full Text] [Related]
2. Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation.
Kutsch N; Gödel P; Voltin CA; Hallek M; Scheid C; Borchmann P; Holtick U
Eur J Haematol; 2024 Jun; 112(6):984-987. PubMed ID: 38316549
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD19 chimeric antigen receptor T-cell therapy for B-cell acute lymphoid leukemia.
Rapoport AP
Haematologica; 2024 Apr; 109(4):1019-1020. PubMed ID: 38562075
[No Abstract] [Full Text] [Related]
4. [Allogeneic hematopoietic stem cell transplantation combined with CD7 CAR-T for the treatment of T lymphoblastic lymphoma: a case report and literature review].
Wang XM; Zhou Y; Zhang JL; Zhou HY; Zhang Q; Sun Q; Li HJ; Xu LY; Yao SN; Yao ZH; Yan DM; Xu KL; Sang W
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):864-865. PubMed ID: 38049342
[No Abstract] [Full Text] [Related]
5. Impact of age on efficacy and safety of chimeric antigen receptor-T in B-cell acute lymphoblastic leukaemia-A systematic review and meta-analysis.
Wu JF; Abid H; Szabo A; Abid MB
Br J Haematol; 2023 Dec; 203(5):e117-e120. PubMed ID: 37814795
[No Abstract] [Full Text] [Related]
6. Cost analysis of patients undergoing allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma from a German healthcare payer perspective.
Ahmadi P; Ghandili S; Jakobs F; Konnopka C; Morgner-Miehlke A; Kröger N; Ayuk F
Bone Marrow Transplant; 2024 Apr; 59(4):572-574. PubMed ID: 38321270
[No Abstract] [Full Text] [Related]
7. Surface Proteomics Reveals CD72 as a Target for
Nix MA; Mandal K; Geng H; Paranjape N; Lin YT; Rivera JM; Marcoulis M; White KL; Whitman JD; Bapat SP; Parker KR; Ramirez J; Deucher A; Phojanokong P; Steri V; Fattahi F; Hann BC; Satpathy AT; Manglik A; Stieglitz E; Wiita AP
Cancer Discov; 2021 Aug; 11(8):2032-2049. PubMed ID: 33727310
[TBL] [Abstract][Full Text] [Related]
8. CAR as Booster to Launch Allogeneic Transplantation in Refractory Leukemia.
Blaise D
N Engl J Med; 2024 Apr; 390(16):1526-1527. PubMed ID: 38657249
[No Abstract] [Full Text] [Related]
9. Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy.
Crombie JL; Jacobson CA; Redd R; Shouse G; Herrera AF; Chow VA; Gauthier J; Mullane E; Cahill K; Kline J; Romancik J; Cohen JB; Saucier A; Houot R; Armand P; Hess B
Haematologica; 2023 Dec; 108(12):3433-3437. PubMed ID: 37259597
[No Abstract] [Full Text] [Related]
10. CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B-cell acute lymphoblastic leukaemia delays platelet recovery and increases risks of cytomegalovirus and Epstein-Barr virus viremia after transplantation.
Li S; Ge J; Zhou S; Zhu W; Han Y; Chen S; Xue S; Wang Y; Qiu H; Wu X; Wu D
Clin Transl Med; 2023 Oct; 13(10):e1459. PubMed ID: 37882317
[No Abstract] [Full Text] [Related]
11. Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes.
Kang L; Tang X; Zhang J; Li M; Xu N; Qi W; Tan J; Lou X; Yu Z; Sun J; Wang Z; Dai H; Chen J; Lin G; Wu D; Yu L
Exp Hematol Oncol; 2020; 9():11. PubMed ID: 32523801
[TBL] [Abstract][Full Text] [Related]
12. CAR-T therapy bridging to allogeneic HSCT provides durable molecular remission of Ph
Kong D; Qu C; Dai H; Li Z; Yin J; Chen S; Kang L; Chen G; Zhu M; Yu L; Wu D; Tang X
Br J Haematol; 2020 Oct; 191(2):e47-e49. PubMed ID: 32700338
[No Abstract] [Full Text] [Related]
13. Donor-derived CAR-T therapy improves the survival of relapsed B-ALL after allogeneic transplantation compared with donor lymphocyte infusion.
Liang Z; Xu H; Zhou X; Yang J; Tu S; He Y; Zhou L; Li Y
Hum Cell; 2023 Sep; 36(5):1716-1728. PubMed ID: 37418233
[TBL] [Abstract][Full Text] [Related]
14. Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia.
Wu L; Chen J; Cai R; Wang X; Liu Y; Zheng Q; Li L
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345104
[TBL] [Abstract][Full Text] [Related]
15. Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy.
Gu J; Liu S; Cui W; Dai H; Cui Q; Yin J; Li Z; Kang L; Qiu H; Han Y; Miao M; Chen S; Xue S; Wang Y; Jin Z; Zhu X; Yu L; Wu D; Tang X
Front Immunol; 2022; 13():858590. PubMed ID: 35371098
[TBL] [Abstract][Full Text] [Related]
16. Relation between auditory difficulties and bortezomib-induced peripheral neuropathy in multiple myeloma: a single-center cross-sectional study.
Giraudet F; Selvy M; Kerckhove N; Pereira B; Barreau F; Nguyen D; Busserolles J; Cabrespine A; Chaleteix C; Soubrier M; Bay JO; Lemal R; Balayssac D
Eur Arch Otorhinolaryngol; 2022 Apr; 279(4):2197-2201. PubMed ID: 35098333
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder.
Yan N; Wang N; Zhang P; Wang G; Mao X; Peng D; Kuang D; Chen L; Zhu L; Zhou J; Zhang Y; Cao Y
Front Oncol; 2021; 11():709370. PubMed ID: 34367995
[TBL] [Abstract][Full Text] [Related]
18. Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.
Yang X; Dai H; Kang L; Qu C; Li Z; Yin J; Qiu H; Fu C; Han Y; Jin Z; Ma X; Zhu X; Yu L; Wu D; Tang X
Hematol Oncol; 2019 Dec; 37(5):655-658. PubMed ID: 31656047
[No Abstract] [Full Text] [Related]
19. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
